Compare stocks

BFLY vs XAIR

Butterfly Network, Inc. and Beyond Air, Inc. Common Stock

Compare the businesses

Butterfly Network, Inc.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly iQ+ Bladder, a specialty product for the bladder scanning market; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. It also provides Butterfly system, which includes probes, related accessories, and software subscriptions to healthcare systems, physicians, and healthcare providers. In addition, the company offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments; and ScanLab, an education-only app that provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. It sells its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Open BFLY dashboard ↗

Beyond Air, Inc. Common Stock

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Open XAIR dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗